Galsulfase
Therapeutic Galsulfase enzyme from the original Naglazyme® commercial drug.
Reference Standard as Aliquots
Product Batch | Therapeutic Expiry Date
| Brand & Origin
| Amount per Aliquot
| Select Quantity | Discount | Price per Aliquot
| |
|---|---|---|---|---|---|---|---|
2023.07 |
Naglazyme® DE |
0.2 mg |
Unit: aliquot(s) |
565,00 €
/aliquot
|
Biosimilars as Aliquots
Access Batch Specific Analytical Information
Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API).
Product Information
Here you will find the product information for the reference product.
Naglazyme® - Galsulfase Reference Drug
| Drug name | Naglazyme® | |||
| INN | Galsulfase | |||
| API type | Galsulfase is a recombinant form of human N-acetylgalactosamine 4-sulfatase and is produced by recombinant DNA technology using mammalian Chinese Hamster Ovary (CHO) cell culture | |||
| Pharmacotherapeutic group | Other alimentary tract and metabolism products, enzymes | |||
| ATC code | A16AB08 | |||
| Target of antibody | ||||
| General function | Galsulfase is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis VI (MPS VI; N-acetylgalactosamine 4-sulfatase deficiency; Maroteaux-Lamy syndrome) | |||
| Short description | ||||
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Galsulfase is an enzyme replacement therapy. Enzyme replacement therapy provides patients with the enzyme they are lacking. The active substance in Naglazyme, galsulfase, is a copy of the human enzyme N-acetylgalactosamine 4-sulfatase. Naglazyme helps to break down the GAGs and stop them building up in the cells. This can improve the symptoms of MPS VI, including the ability of patients to move about. | |||
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | In studies, the most common side effects with Naglazyme (seen in more than 1 patient in 10) were ear pain, dyspnoea (difficulty breathing), abdominal pain and general pain. Patients can also have reactions to the infusion (such as fever, chills, rash and hives). Naglazyme should not be used in people who may be hypersensitive (allergic) to galsulfase or any of the other ingredients. | |||
| Original license holder | ||||
| Marketing authorisation numbers | EU/1/05/324/001 | |||
| Marketing authorisation holder | BioMarin International Limited Shanbally, Ringaskiddy, County Cork, P43 R298 Ireland | |||
| Name of the manufacturer of the biological active substance | BioMarin Pharmaceutical Inc. 46 Galli Drive, Novato, CA 94949 United States of America | |||
| Name and address of the manufacturer(s) responsible for batch release | BioMarin International Limited Shanbally, Ringaskiddy County Cork, P43 R298 Ireland | |||
| Max shelf life | 3 years | |||
| Storage conditions | 2°C - 8°C | |||
| List of excipients | Sodium chloride - Sodium phosphate monobasic, monohydrate - Sodium phosphate dibasic, heptahydrate - Polysorbate 80 - Water for injections |
Support
Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!
Ready to simplify your sourcing?
Here’s how to get started:
Select Your Licensed Molecules
Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!
Get a Quote
Receive a confidential, non-binding quote for the molecule(s) you choose.
Get Qualified & We Deliver
Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.
Do you have a question you'd like to ask us?
Here’s how to get started:
